The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer
Information source: National University Hospital, Singapore
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cancer (Advanced Stage)
Intervention: 5-Fluorouracil (Drug)
Phase: Phase 2
Status: Active, not recruiting
Sponsored by: National University Hospital, Singapore Official(s) and/or principal investigator(s):
Thomas Soh, MBBS, Principal Investigator, Affiliation: National University Hospital, Singapore
Summary
The purpose of this study is:
1. To determine the proportion of Asian patients achieving a target area under the curve
(AUC) of 20-24 mg. h/L using a pharmacokinetically guided 5-fluorouracil (5-FU) dose
2. To determine the safety and tolerability of dose adjusted 5-FU
3. To correlate 5-FU pharmacokinetics with gene variants associated with the 5-FU pathway
and with clinical outcomes
Based on Western data, levels of 5-FU are highly variable when doses are based on BSA. A
relationship between systemic plasma levels of 5-FU and treatment toxicity and efficacy
exists. Whilst pharmacokinetically-guided dose management has been shown to improve 5-FU
efficacy and tolerance, there is currently no data in Asian patients using this approach.
Using pharmacokinetically guided 5-FU-dose adjustment, the investigators hypothesize the
proportion of Asian patients achieving a target AUC of 20-24 mg. h/L is similar to that of
Caucasians.
METHODS:
This is an open, non-randomised single center Phase II study evaluating dose adjusted 5-FU
in patients receiving de Gramont, FOLFIRI or mFOLFOX-6 schedules.
Clinical Details
Official title: The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: AUC of 20-24 mg.h/L
Eligibility
Minimum age: 21 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients aged = 21 years to 80 years
- Histologically proven advanced stage carcinoma where De Gramont, FOLFIRI or mFOLFOX-6
regimen is indicated.
- No more than one line of prior chemotherapy for advanced stage disease
- Measurable disease according to RECIST criteria or evaluable disease
- Karnofsky performance status of at least 70% or electrocorticogram performance
status ? 2
- A life expectancy of at least 3 months
- absolute neutrophil count > 1. 5 x 10^9/L
- Platelet count > 100 x 10^9/L.
- Total bilirubin > 1. 5x upper limits of normal reference range (ULN)
- AST/ALT levels > 2. 5x upper limit of normal. If hepatic metastases are present, these
parameters could be ? 5x the ULN.
- Women of reproductive age and men must agree to practice effective contraception
during the entire study period. Postmenopausal women must have been amenorrheic for
at least 12 months to be considered of non-child-bearing potential. Females with
childbearing potential must have a negative serum pregnancy test within 7 days prior
to study enrollment. Should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately.
- Signed informed consent
Exclusion Criteria:
- Received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy,
hormonal, biologic or any investigational therapy within 21 days prior to study drug
administration (6 weeks for mitomycin or nitroureas) and have not recovered from
therapy.
- Patients who have not recovered from major surgery
- Subjects with treated brain metastases are eligible provided they are asymptomatic
and do not require corticosteroids (must have discontinued steroids at least 1 week
prior to study drug administration).
- Clinically significant cardiac disease, e. g. myocardial infarction within the last 12
months.
- Known HIV infection
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, other serious uncontrolled concomitant disease, psychiatric illness/
social situation that would limit study compliance.
- Known allergies to any component of the drug regime
- Organ allografts
- Known dihydropyrimidine dehydrogenase deficiency
Locations and Contacts
National University Hospital, Singapore 119074, Singapore
Additional Information
Related publications: Meta-analysis Group In Cancer, Piedbois P, Rougier P, Buyse M, Pignon J, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Levy E. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998 Jan;16(1):301-8. Meta-Analysis Group In Cancer, Lévy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, Thirion P. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998 Nov;16(11):3537-41.
Starting date: June 2009
Last updated: June 17, 2015
|
